ANN ARBOR, Mich., May 07, 2018 -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it will present at the 2018 Disruptive Growth & Healthcare Conference on Tuesday, May 8, 2018 at 11:10 a.m. EDT in New York, NY.
Chief Executive Officer Gerald Solensky, Jr. will provide an overview of Zomedica’s business during his live presentation and will be available to participate in one-on-one meetings with investors registered to attend the conference.
Solensky is also part of a panel discussion on “Disrupting Crop Productivity/Sustainability, Farming & Animal Health” at 8:15 a.m. EDT.
2018 Disruptive Growth & Healthcare Conference
Date: Tuesday, May 8, 2018
Time: Panel Discussion, 8:15 a.m. EDT and Company Overview, 11:10 a.m. EDT
Location: Reed Smith LLP, 599 Lexington Avenue, New York, NY 10022
Investors and other interested parties will be able to access a live webcast of the company presentation by visiting Zomedica’s website at http://investors.zomedica.com. A replay of the webcast will be accessible on the Zomedica website for 90 days following the event.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Investor Relations Contacts
Shameze Rampertab, CPA, CA
[email protected]
+1 647.283.3630
PCG Advisory Group
Kirin Smith, COO
[email protected]
+1 646.863.6519
www.pcgadvisory.com
Media Contact
Andrea Eberle
[email protected]
+1 734.369.2555


Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 



